Generic Name: dacomitinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Pfizer

Approval Status: Experimental

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Vizimpro is a kinase inhibitor approved for people with metastatic non-small-cell lung cancer (NSCLC) with certain EGFR mutations who are being treated for the first time.

General Info

Vizimpro interferes with epidermal growth factor receptor (EGFR) proteins that play a role in cancer cell growth and development of blood vessels that feed tumors. Certain EGFR mutations promote lung tumor growth and metastasis.

The ARCHER 1050 trial, which enrolled mostly previously untreated people with inoperable metastatic lung cancer with specific EGFR exon 19 or 21 mutations, showed that Vizimpro delayed disease progression longer than chemotherapy. Vizimpro was first approved in 2018.


Dosing Info:

Vizimpro is a once-daily pill that can be taken with or without food.

Side Effects

Common side effects include diarrhea, decreased appetite, weight loss, skin rash, nail problems, mouth sores, dry skin, hair loss and itching. Potential serious side effects may include severe diarrhea, lung problems and severe skin reactions. Vizimpro can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: October 23, 2019